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Abstract
Background: We report the first successful treatment of limbal lesions and corneal erosion experienced by a breast
cancer patient undergoing trastuzumab treatment.
Case presentation: A 49-year-old Caucasian woman with early stage breast cancer was treated with adjuvant
trastuzumab and subsequently showed persistent bilateral corneal marginal infiltrates resistant to topical steroid
and antibiotic treatment. Autologous serum was applied in the conjunctival sac as an experimental treatment to
antagonize the inhibitory effect of the HER2 receptor antibody on the corneal epithelial cells. Topical application of
autologous serum led to rapid improvement of the ulcerative keratitis, with complete healing of the corneal defect
after 7 days. Continued administration of the serum allowed the resumption of trastuzumab therapy without any
further side effects.
Conclusions: Persistent bilateral corneal marginal infiltrates may occasionally arise as a side effect of trastuzumab
treatment. Topical medication with autologous serum may be an effective therapeutic option for the ocular side
effects of trastuzumab therapy.
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Background
Trastuzumab, a monoclonal antibody that targets breast
cancers which overexpress the HER2 receptor, improves
the response rate, time to progression, and overall survival
of both metastatic and adjuvant patients [1–4]. Recently,
trastuzumab was also shown to be effective in the treat-
ment of metastatic HER2+ gastric cancer [5]. Clinically,
the most important side effect of trastuzumab is cardio-
toxicity, which is reported in 2.6 to 4.5 % of patients [6].
This side effect remains the only limiting factor in the use
of trastuzumab and may appear as an asymptomatic de-
crease in the left ventricular ejection fraction or symptom-
atic congestive heart failure [7, 8]. The pathophysiology,
which differs from the cardiotoxicity of anthracyclines, is
still poorly understood but the important physiological
role played by the HER2 pathway in the function of
cardiomyocytes is well established [9].
The HER family of receptor tyrosine kinases (EGFR,
also termed ErbB1/HER1, ErbB2/Neu/HER2, ErbB3/
HER3, and ErbB4/HER4) and their ligands, have been
shown to be involved in cell differentiation, proliferation,
migration, and carcinogenesis [10, 11]. HER1, HER2 and
HER3 are also expressed by corneal, limbal and conjunc-
tival epithelia [12]. Ocular side effects of trastuzumab in
human subjects are not commonly observed [13]. In the
GeparQuattro study, conjunctivitis was reported as a
side effect in 2.5 % of patients [14]. In a different study,
using a related drug, trastuzumab-DM1 which is a HER2
antibody-cytotoxic conjugate, ocular side effects were
reported for 28 % of patients [15]. These side effects,
which were generally mild and tolerable, included: dry
eyes, increased lacrimation, mild subjective blurring of
vision, and conjunctivitis. ErbB2 serves as a critical com-
ponent that couples the ErbB receptor to the migration
machinery of corneal epithelial cells [16]. Here we report
the successful treatment of progressive corneal ulcerative
damage which arose due to treatment with trastuzumab.
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Case presentation
A 49 year old Caucasian woman with a ductal carcinoma
of the right breast (pT2N1, ER+, PgR+, HER2+ IIC,
Ki 67 70 %), after external quadrantectomy, received
sequential adjuvant treatment of adriamycin and cyclo-
phosphamide for four cycles, as well as four cycles of
docetaxel and trastuzumab, and radiation on the residual
mammary gland. This was then followed by 14 additional
treatments with trastuzumab every 3 weeks as monother-
apy. The patient did not suffer any co-morbidities and was
not taking any other medications during treatment. The
cytotoxic treatment was well tolerated; however, 10 days
after the 12th dose of trastuzumab in monotherapy the
patient complained of burning and watery eyes, a sensa-
tion of a foreign body in both eyes, although mainly in the
right eye, and impaired vision. These sensations were not
due to mechanical trauma to the eyes.
Conjunctival congestion with perikeratic hyperemia
and light perilimbal conjunctival edema with corneal
marginal infiltrates accompanied by epithelial defects
were observed in both eyes (Fig. 1). No further ocular
alteration was seen. Polymerase chain reaction testing
for herpes simplex virus was negative, and cultures of
conjunctival secretion were sterile. Complete serum im-
munology balance, as well screening for autoantibodies,
was negative.
Topical therapy with steroid and antibiotics was started
and the right eye was bandaged. Despite initial improve-
ment, the patient’s symptoms worsened after the 13th
dose of trastuzumab. As such, we hypothesized a link
between HER2 pathway inhibition in the cornea and the
ocular side effects. Among the possible strategies to pre-
vent the drug effects on the HER2 pathway in the corneal
epithelium, maintenance of sustained activation by admin-
istration of a topical serum ligand seemed was proposed
as the best solution. Therefore, the 14th administration of
trastuzumab was delayed by 1 week, and a sample of
peripheral blood was collected. The possibility that a sig-
nificant concentration of trastuzumab was present in the
serum is unlikely due its half-life of 2–12 days. Serum was
separated by centrifugation under sterile conditions and
stored without dilution at −20 °C. Seven days before the
14th administration of trastuzumab, three drops of serum
in each eye was instilled twice per day. Epithelial healing
was observed shortly after the onset of treatment with
autologous serum, and marginal infiltrates disappeared
after 7 days, leaving no haze or scar (Fig. 2). Trastu-
zumab therapy was restarted without relapse of any
of the ocular symptoms. Administration of topical autolo-
gous serum was continued in conjunction with trastuzu-
mab for the duration of the patient’s treatment. As a
result, no further corneal or ocular disease was observed
in post-therapy follow-up.
Conclusion
Epidermal growth factor receptors are strongly expressed
on the surface of basal epithelium cells of the corneal lim-
bus, conjunctive, and throughout the corneal epithelium
[12]. EGFR stimulates proliferation and migration of epi-
thelial cells and is generally considered to be the major
effector molecule in corneal wound healing [16]. EGFR
inhibition has been reported to affect epithelial cell prolif-
eration and stratification during corneal epithelial wound
healing, and thus, may play a role in maintaining corneal
epithelium thickness [17]. The relative role of the
HER2neu member of the EGFR family in maintaining
and restoring corneal epithelium integrity is not well
known, but is considered crucial in the association of
activated-EGFR tyrosine kinase to the migration of cor-
neal epithelial cells [18]. Based on this, we hypothesized
Fig. 1 Digital image of the right eye (small picture). Limbal congestion
with hyperemia and fluorescein staining of an epithelial defect overlying
a marginal infiltrate at 9 o’clock limbus (in magnification)
Fig. 2 Digital image of the right eye (small picture). Evaluation after
therapy with topical autologous serum. The corneal epithelium is
fully healed and the marginal infiltrate is not detectable
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that trastuzumab-induced HER2 inhibition may have
impaired corneal epithelium turnover in our patient.
If correct, then completion for HER2 signaling by provid-
ing ligands of HER2 heterodimers could restore normal
proliferation and migration of the corneal epithelial cells.
Alternatively, if the mechanism of corneal damage had
been immunologically mediated by antibody-dependent
cell cytotoxicity, receptor internalization following ligand
binding would have prevented antigen recognition by the
HER2 antibody. Although the patient’s clinical improve-
ment in this case report may also be a result of the seven
day delay in further trastuzumab therapy, the lack of
corneal damage when trastuzumab therapy was recom-
menced underlines the protective action on the cornea of
the topical autologous serum treatment. Whatever the
mechanism of corneal damage, the intervention strategy
that we employed allowed us to continue the adjuvant
treatment of the patient. It is important to note that this
observation does not represent a “proof-of-concept” of
pathogenesis of corneal damage during treatment with
trastuzumab. In addition, it does not demonstrate a mech-
anism of local action of patient-derived serum, but the
successful clinical result, and the novel approach, are intri-
guing and warrant in-depth study. Indeed, this treatment
method may become more important with time as the
HER2 pathway is now a useful target for therapy in
10–20 % of metastatic gastric cancer, whereas for HER+
metastatic breast cancer tratuzumab has been found
to be more effective when combined with Pertuzumab, an
HER–dimerization inhibitor [19].
As the number of patients undergoing chemotherapy
with trastuzumab for HER+ cancer increases it can be ex-
pected that the risk of damaging side-effects to corneal tis-
sue will also increase. As such, the successful treatment of
limbal lesions and corneal erosion experienced by the
breast cancer patient in this case report provide a poten-
tially important new therapy for patients who experience
these side effects as a result of trastuzumab therapy.
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